Stay updated on Biogen Press Releases

Sign up to get notified when there's something new on the Biogen Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Biogen Press Releases page

  1. Check
    4 days ago
    Change Detected
    Summary
    Added TIME Best Inventions feature and a new date; removed an older date and a participation note. Overall, the page now emphasizes the TIME recognition for LEQEMBI and updates the timeline.
    Difference
    100%
    Check dated 2025-10-20T05:54:33.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    Add new data points (Dravet data, donation, LEQEMBI availability) and remove older lupus assets, a rolling submission note, and conference participation; reflects updated business and clinical news rather than a complete content overhaul.
    Difference
    97%
    Check dated 2025-10-13T03:03:33.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Update: adds a China approval-related news item for LEQEMBI and removes an earlier press release about Zorevunersen for Dravet Syndrome.
    Difference
    97%
    Check dated 2025-10-05T17:31:40.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    Additions introduce recent Biogen news items (new approvals, regulatory updates, and upcoming earnings), while deletions remove older Biogen highlights (earlier approval, data presentations, and EU launch details). The net effect is a refresh to current events/news content.
    Difference
    92%
    Check dated 2025-09-28T10:39:24.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    New strategic actions and regulatory milestones added (deal, approval, conference participation); older financial results and prior study updates removed.
    Difference
    100%
    Check dated 2025-09-21T06:45:57.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The webpage has been updated to include new information about Biogen's initiatives in lupus and Alzheimer's disease, while removing previous data on LEQEMBI's maintenance dosing and its benefits over four years. Notably, the new content emphasizes Biogen's participation in healthcare conferences and highlights potential advancements in treatment for Dravet Syndrome.
    Difference
    100%
    Check dated 2025-09-06T21:09:28.000Z thumbnail image

Stay in the know with updates to Biogen Press Releases

Enter your email address, and we'll notify you when there's something new on the Biogen Press Releases page.